This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Seaweed extracts matched or exceeded the enzyme-inhibiting activity of prescription drugs: Palmaria palmata peptides matched captopril for ACE-1 inhibition, and Alaria esculenta polyphenols outperformed both acarbose and orlistat for alpha-amylase and lipase inhibition.
Why it matters
Metabolic syndrome (high blood pressure, diabetes, obesity) affects millions. Natural seaweed-derived alternatives could provide dietary approaches to managing these conditions with fewer side effects.
The numbers in context
P. palmata peptides ACE-1 IC50: 94.29 mcg/mL (vs captopril 91.83). A. esculenta polyphenols alpha-amylase IC50: 147.04 (vs acarbose 185.67). A. esculenta lipase IC50: 106.21 (vs orlistat 139.74). U. lactuca polysaccharides alpha-amylase IC50: 168.06 (vs acarbose 185.67).
How the study worked
In vitro enzyme inhibitory assays for ACE-1, alpha-amylase, and lipase. Compared seaweed extracts (peptides, polyphenols, polysaccharides) to reference drugs. Proximate analysis of protein, fiber, and fatty acid content.
Who was studied
Three seaweed species tested against metabolic syndrome enzymes
What this study cannot tell us
In vitro assay only. Enzyme inhibition in a test tube does not guarantee in vivo efficacy. Bioavailability after oral consumption unknown. Seaweed composition varies by season and location.
Read the original research
Alaria esculenta, Ulva lactuca, and Palmaria palmata as Potential Functional Food Ingredients for the Management of Metabolic Syndrome.
Foods (Basel, Switzerland), 14(2)
Citation
Shannon, Emer; Hayes, Maria. (2025). Alaria esculenta, Ulva lactuca, and Palmaria palmata as Potential Functional Food Ingredients for the Management of Metabolic Syndrome.. Foods (Basel, Switzerland), 14(2). https://doi.org/10.3390/foods14020284